Cevostamab Consolidation Following BCMA CAR T Cell Therapy: Primary Analysis of the Phase 2 "STEM" (Sequential T Cell-Engagement for Myeloma) Trial (IMS 2026) - Sep 11, 2026 - Abstract #LBA-17; Pres time: Sep 25, 2026; P2 | " 27 pts (20M, 7F; median age 64; 21 White, 6 Black) enrolled, with median 4 (range 2-10) prior lines, 74% triple-class refractory, 11% prior BCMA therapy, and 11% prior talquetamab...93% received cilta-cel and 7% ide-cel... Cevo consolidation post-CAR T cells is feasible and well-tolerated in late-line RRMM, with 89% of pts showing sustained MRD-neg sCR at 1 year and promising 2-year PFS."
CAR T-Cell Therapy • Late-breaking abstract • P2 data • Cough • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Respiratory Diseases • Thrombocytopenia
|
|
Adam D. Cohen1; Sandra Susanibar-Adaniya1; Fatma Yilmaz2; Alfred Garfall1; Dan T. Vogl3; Shivani Kapur1; Adam Waxman1; Danielle Zubka1; WeiTing Hwang3; Cynthia Diaczynsky1; Heta Patel3; Elina Thai4; Alan Zheng4; Alexandria Raday4; Katie Alexander4; Matthew Ho1; Luca Paruzzo1; Marco Ruella1; Joseph Fraietta4; Edward Stadtmauer1
|